Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Ono Takes over Orphan Designation for 2 Products Including MEK Inhibitor from Array BioPharma
April 4, 2018
- MHLW to Discuss Stockpiling of Xofluza, Tamiflu Generics in FY2018
April 3, 2018
- Use of Big Data Entering New Stage with Launch of MID-NET, Enforcement of New Law
April 3, 2018
- AMED Out-Licenses 2 Compounds in Drug Discovery Support Initiative
April 2, 2018
- Chuikyo Begins Debate on Sales Tax Hike, Agrees on Drug Price Survey in 2018
April 2, 2018
- MHLW Orders Package Insert Revisions for Antibacterial Drugs
March 29, 2018
- Sakigake Status Goes to World’s 1st Renal-Function Improving Agent, BBB-Penetrating Hunter Syndrome Med and 4 More Drugs
March 28, 2018
- MHLW’s Panel to Discuss First Revision of Anti-RA Measures in 7 Years; Proper Use of Biologics to Be a Focus
March 28, 2018
- Council OKs Public Knowledge-Based Application for Elplat Triplet
March 26, 2018
- MHLW Approves Hemlibra, Shingrix, Ozempic, and More
March 26, 2018
- 16 Possible Topics for New Guidelines Including Continuous Manufacturing to Be Discussed at First ICH “Interim Meeting” this Week
March 26, 2018
- Gilteritinib, 3 Other APIs Earn Orphan Designation
March 23, 2018
- MHLW to Purchase, Stockpile Enough Inavir for 3.81 Million People, Avigan for 1.91 Million People
March 23, 2018
- MHLW Orders Label Revisions for Samsca Acute Liver Failure Added to Significant ADR List
March 22, 2018
- Healthcare Experts at Odds over Nonprescription Switches of 3 PPIs
March 20, 2018
- Price Adjustments Based on Cost-Effective Assessments “Impossible”: Prof. Sakamaki
March 20, 2018
- MHLW to Discuss Creation of Post-Launch Premium for Add’l Indications: Official
March 20, 2018
- MHLW Health Policy Chief Questions Volume-Focused Sales Strategies, Urges Drug Makers to Shift to Healthy Lifespan Extension
March 19, 2018
- Lift Ban on Coadministration of Adrenalin Medications with Alpha-blocking Antipsychotic Drugs: MHLW Panel
March 19, 2018
- PMDA Estimates MID-NET Will Be Used for PMS for 18 Products Annually
March 16, 2018
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…